Sutro Biopharma Balance Sheet Health
Financial Health criteria checks 6/6
Sutro Biopharma has a total shareholder equity of $111.2M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $451.8M and $340.6M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$388.25m |
| Equity | US$111.22m |
| Total liabilities | US$340.61m |
| Total assets | US$451.83m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: S09's short term assets ($405.8M) exceed its short term liabilities ($131.3M).
Long Term Liabilities: S09's short term assets ($405.8M) exceed its long term liabilities ($209.3M).
Debt to Equity History and Analysis
Debt Level: S09 is debt free.
Reducing Debt: S09 has no debt compared to 5 years ago when its debt to equity ratio was 10.3%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: S09 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: S09 has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 21.9% each year.